Leisha A. Emens, MD, PhD, discusses the incidence and treatment of immune-related adverse events in ovarian cancer.
Leisha A. Emens, MD, PhD
Advertisement
Articles by Leisha A. Emens, MD, PhD
Leisha A. Emens, MD, PhD, discusses the combination of checkpoint inhibitors and PARP inhibitors in ovarian cancer.
Leisha A. Emens, MD, PhD, discusses a potential future with immunotherapy in ovarian cancer.
Advertisement
Latest Updated Articles
Dr. Emens on the Future of Immunotherapy in Ovarian CancerDecember 23rd 2019
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
3
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
4
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
5